Page 100 - 南京医科大学学报自然科学版

第41卷第8期
·1202 · 南 京 医 科 大 学 学 报 2021年8月

样本量较少，且不同病理类型患者接受的含铂化疗 alone versus gefitinib plus chemotherapy for non⁃small⁃
方案不同，存在一定的局限性，未来可能需要大样 cell lung cancer with mutated epidermal growth factor re⁃
本前瞻性研究进行验证。 ceptor：NEJ009 Study［J］. J Clin Oncol，2020，38（2）：
115-123
［参考文献］
［9］ YING C，MURAKAMI H，YANG P C，et al. Randomized
［1］ SARA⁃ELENA R，ALFIERI R，LA MONICA S，et al. Com⁃ phase II trial of gefitinib with and without pemetrexed as
bination of EGFR ⁃ TKIs and chemotherapy in advanced first⁃line therapy in patients with advanced nonsquamous
EGFR mutated NSCLC：review of the literature and future non ⁃ small ⁃ cell lung cancer with activating epidermal
perspectives ［J］. Crit Rev Oncol/Hematol， 2020， growth factor receptor mutations［J］. J Clin Oncol，2016，
146102820 34（27）：3258-3266
［2］ PETER T H，VYSE S，HUANG P H. Rare epidermal ［10］ 王国群，吴魏芹，王 茜，等. 盐酸埃克替尼联合化疗对
growth factor receptor（EGFR）mutations in non⁃small cell 比盐酸埃克替尼单药治疗晚期非小细胞肺癌的回顾性
lung cancer［J］. Semin Cancer Biol，2020，61：167-179 分析［J］. 南京医科大学学报（自然科学版），2019，39
［3］ SCHULER M，PAZ⁃ARES L，SEQUIST L V，et al. First⁃ （5）：727-731
line afatinib for advanced EGFRm+ NSCLC：analysis of ［11］ ZHU J Q，ZHONG W Z，ZHANG G C，et al. Better surviv⁃
long⁃term responders in the LUX⁃Lung 3，6，and 7 trials al with EGFR exon 19 than exon 21 mutations in gefitinib⁃
［J］. Lung Cancer，2019，133：10-19 treated non⁃small cell lung cancer patients is due to differ⁃
［4］ FENG W，ZHENG H R，ZHANG P F，et al. OPTIMAL ential inhibition of downstream signals［J］. Cancer Lett，
and ENSURE trials ⁃ based combined cost ⁃ effectiveness 2008，265（2）：307-317
analysis of erlotinib versus chemotherapy for the first⁃line ［12］ HONG S D，GAO F F，FU S，et al. Concomitant genetic al⁃
treatment of Asian patients with non⁃squamous non⁃small⁃ terations with response to treatment and epidermal growth
cell lung cancer［J］. BMJ Open，2018，8（4）：e20128 factor receptor tyrosine kinase inhibitors in patients with
［5］ WU Y L，SAIJO N，THONGPRASERT S，et al. Efficacy EGFR⁃mutant advanced non⁃small cell lung cancer［J］.
according to blind independent central review：Post⁃hoc JAMA Oncology，2018，4（5）：739
analyses from the phase Ⅲ ，randomized，multicenter， ［13］ SHI Y K，WANG L，HAN B H，et al. First⁃line icotinib
IPASS study of first⁃line gefitinib versus carboplatin/pacli⁃ versus cisplatin/pemetrexed plus pemetrexed mainte⁃
taxel in Asian patients with EGFR mutation⁃positive ad⁃ nance therapy for patients with advanced EGFR mutation⁃
vanced NSCLC［J］. Lung Cancer，2017，104：119-125 positive lung adenocarcinoma（CONVINCE）：a phase 3，
［6］ SHENG M M，WANG F，ZHAO Y G，et al. Comparison of open⁃label，randomized study［J］. Ann. Oncol.，2017，28
clinical outcomes of patients with non⁃small⁃cell lung can⁃ （10）：2443-2450
cer harbouring epidermal growth factor receptor exon 19 ［14］ XU L S，QI Q，ZHANG Y，et al. Combination of icotinib
or exon 21 mutations after tyrosine kinase inhibitors treat⁃ and chemotherapy as first ⁃ line treatment for advanced
ment：a meta⁃analysis［J］. Eur J Clin Pharmacol，2016，72 lung adenocarcinoma in patients with sensitive EGFR mu⁃
（1）：1-11 tations：a randomized controlled study［J］. Lung Cancer，
［7］ JAMES C H Y，WU Y L，SCHULER M，et al. Afatinib ver⁃ 2019，133：23-31
sus cisplatin⁃based chemotherapy for EGFR mutation⁃pos⁃ ［15］ CUI J D，ZHANG Y，SU D，et al. Efficacy of combined ic⁃
itive lung adenocarcinoma（LUX⁃Lung 3 and LUX⁃Lung otinib and pemetrexed in EGFR mutant lung adenocarci⁃
6）：analysis of overall survival data from two randomised， noma cell line xenografts［J］. Thorac Cancer，2018，9（9）：

phase 3 trials［J］. Lancet Oncol，2015，16（2）：141-151 1156-1165
［8］ YUKIO H，MORITA S，SUGAWARA S，et al. Gefitinib ［收稿日期］ 2021-03-27